ABBV AbbVie Inc.
USHealthcareAs of 2026-07-09 11:25
Why ABBV matters now
AbbVie Inc. (ABBV) is a US stock in Healthcare. The latest InvestLog snapshot shows $251.75 with -0.39% on the session and $444.79B in market capitalization; recent performance reads 1-month +1.34% and YTD -5.19%.
The latest financial table shown here is Q1 2026, with revenue of $15.00B, net income of $699.0M, and EPS of $0.39. Investors can compare that operating picture with valuation signals such as P/E 87.05 and FCF yield 5.5%.
The latest indexable market news headline is "AbbVie: Maintaining My Strong Buy Rating After Label Expansion" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $259.00; recent insider activity includes AUSTIN ROXANNE S filing A-Award; recent congressional disclosure data includes Ro Khanna Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
87.05
PEG
—
P/B
13.97
P/S
6.09
EV/EBITDA
26.37
DCF Value
$138.45
FCF Yield
5.5%
Div Yield
3.1%
Margins & Returns
Gross Margin
70.7%
Operating Margin
27.6%
Net Margin
5.8%
ROE
68.0%
ROA
2.7%
ROIC
10.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.00B | $699.0M | $0.39 |
| Q4 2025 | $16.62B | $1.82B | $1.02 |
| FY 2025 | $61.16B | $4.23B | $2.37 |
| Q3 2025 | $15.78B | $186.0M | $0.10 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$256.92
Target (Median)
$259.00
Target Range
$223.00 - $298.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
US
Exchange
—
Beta
0.31
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.